Rybelsus 1.5 mg tablets

DRUG2 trials

Sponsors

AstraZeneca AB, Novo Nordisk A/S

Conditions

Overweight and obesitytype 2 diabetes mellitus

Phase 3

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)

Not yet recruitingCTIS2025-523933-24-00

AstraZeneca ABtype 2 diabetes mellitus

Target: 110Updated: 2026-07-22

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Not yet recruitingCTIS2025-524626-18-00

Novo Nordisk A/SOverweight and obesity

Target: 180Updated: 2026-08-11